🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

478 results for “capsule” Clear

  1. Zelvina 5 mg hard capsules, Dexamethasone Tablets BP 2.0mg, Fortecortin® 2 mg Tabletten, Revlimid 25 mg hard capsules, Zelvina 10 mg hard capsules, Revlimid 5 mg hard capsules, Dexamethason 8 mg GALEN® Tabletten, Revlimid 10 mg hard capsules, Dexamethason 8 mg JENAPHARM®, Zelvina 25 mg hard capsules, DARZALEX 1800 mg solution for injection

    GlaxoSmithKline

    Multiple myeloma

    phase 3 small molecule active

    1 trial

  2. Zeposia 0.23 mg hard capsules Zeposia 0.46 mg hard capsules, Zeposia 0.23 mg hard capsules Zeposia 0.46 mg hard capsules, Zeposia 0.92 mg hard capsules

    Celgene Europe Limited

    Moderately to Severely Active Crohn's Disease

    phase 3 small molecule active

    1 trial

  3. a compound glutamine capsule

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Mucositis

    phase 3 small molecule active

    1 trial

  4. a compound glutamine capsule/a compound glutamine capsule simulated placebo

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Mucositis

    phase 3 small molecule active

    1 trial

  5. camizestrant, Arimidex® 1 mg Filmtabletten, IBRANCE 75 mg hard capsules, Placebo to match camizestrant, Placebo to match Arimidex, LEUPRORELIN ACETATE, IBRANCE 125 mg hard capsules, IBRANCE 75 mg film-coated tablets, IBRANCE 100 mg hard capsules, IBRANCE 75 mg hard capsules, IBRANCE 100 mg hard capsules, IBRANCE 125 mg film-coated tablets, IBRANCE 100 mg film-coated tablets, IBRANCE 125 mg hard capsules, IBRANCE 100 mg hard capsules, Camizestrant, IBRANCE 125 mg hard capsules, IBRANCE 75 mg hard capsules, G

    AstraZeneca AB

    Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

    phase 3 small molecule active

    1 trial

  6. tacrolimus capsule

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lupus Nephritis

    phase 3 small molecule terminated

    1 trial

  7. the Shouhui Tongbian Capsule

    The First People's Hospital of Lianyungang

    OIC

    phase 3 small molecule active

    1 trial

  8. Advagraf 0.5 mg prolonged-release hard capsules, Advagraf 1 mg prolonged-release hard capsules, Advagraf 1 mg prolonged-release hard capsules, Advagraf 5 mg prolonged-release hard capsules, Advagraf 1 mg prolonged-release hard capsules, Advagraf 0.5 mg prolonged-release hard capsules, Advagraf 0.5 mg prolonged-release hard capsules, Advagraf 1 mg prolonged-release hard capsules, Advagraf 0.5 mg prolonged-release hard capsules, Advagraf 1 mg prolonged-release hard capsules, Advagraf 0.5 mg prolonged-release

    Astellas Pharma GmbH

    Prophylaxis of primary liver, kidney, heart, lung, and intestinal organ transplant rejection

    phase 2 small molecule active

    1 trial

  9. Alkotinib Capsules

    Suzhou Zelgen Biopharmaceuticals Co.,Ltd

    ALK-positive Non-small Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  10. Alunbrig 30 mg film-coated tablets, CRIZOTINIB, LORLATINIB, Zykadia 150 mg hard capsules, ALECTINIB

    The George Institute

    locally advanced (stage III) and not suitable for curative treatment, or metastatic (stage IV) ALK+ NSCLC, ALK+ NSCLC

    phase 2 small molecule active

    1 trial

  11. BRONCHO-VAXOM Children Capsules placebo, BRONCHO-VAXOM, 3,5mg, kapsułki

    Lacuna Pharma Pty Ltd

    Recurrent wheezing

    phase 2 small molecule active

    1 trial

  12. Bactrim 160 mg + 800 mg compresse, CHLORPHENAMINE MALEATE, ALLOPURINOL, BRUKINSA 80 mg hard capsules, DEXAMETHASONE PHOSPHATE, VENETOCLAX, VENETOCLAX, Gazyvaro 1,000 mg concentrate for solution for infusion., Lamivudina Mylan 150 mg compresse rivestite con film, VENETOCLAX, PARACETAMOL

    Fondazione Telethon ETS

    Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  13. Braftovi 75 mg hard capsules, Erbitux 5 mg/mL solution for infusion

    CERO THERAPEUTICS HOLDINGS, INC.

    BRAF V600E-MUTATED LOCALISED COLON OR UPPER RECTUM CANCER

    phase 2 small molecule active

    1 trial

  14. Braftovi 75 mg hard capsules, LIBTAYO 350 mg concentrate for solution for infusion., Mektovi 15 mg film-coated tablets, Fianlimab, Braftovi 50 mg hard capsules

    Disc Medicine

    Melanoma

    phase 2 small molecule active

    1 trial

  15. Braftovi 75 mg hard capsules, Mektovi 15 mg film-coated tablets

    CERO THERAPEUTICS HOLDINGS, INC.

    BRAFV600E-mutant metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  16. Budigalimab, Sorafenib STADA 200 mg Filmtabletten, Livmoniplimab, Kisplyx 4 mg hard capsules

    AbbVie Deutschland GmbH & Co. KG

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  17. CARBOPLATIN, Datopotamab deruxtecan, Inflectra 100 mg powder for concentrate for solution for infusion, ETOPOSIDE, CISPLATIN, Inflectra 100 mg powder for concentrate for solution for infusion, Inflectra 100 mg powder for concentrate for solution for infusion, Mycophenolate Mofetil Accord 250 mg capsules, Inflectra 100 mg powder for concentrate for solution for infusion, TAGRISSO 80 mg film-coated tablets, Inflectra 100 mg powder for concentrate for solution for infusion, IMFINZI 50 mg/mL concentrate for sol

    AstraZeneca AB

    Advanced Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  18. CORT113176, CORT113176, Placebo to Dazucorilant softgel capsule

    CORCEPT THERAPEUTICS INC

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule active

    1 trial

  19. CRD-4730, Encapsulation of microcrystalline cellulose into HPMC capsules to match the CRD-4730 active capsules in appearance

    Lacuna Pharma Pty Ltd

    Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

    phase 2 small molecule active

    1 trial

  20. CRIZOTINIB, CRIZOTINIB, XALKORI 200 mg hard capsules, CRIZOTINIB, CRIZOTINIB, CRIZOTINIB, XALKORI 250 mg hard capsules, Torisel 30 mg concentrate and solvent for solution for infusion

    Disc Medicine

    Neuroblastoma (NBL), Rhabdomyosarcoma (RMS), Inflammatory Myofibroblastic Tumors (IMT), Other ALK/ROS1/MET-positive malignancies, Anaplastic Large Cell Lymphoma (ALCL)

    phase 2 small molecule active

    1 trial

  21. CYSTAGON 150 mg hard capsules

    The George Institute

    Infectious diseases of respiratory system (COVID-19)

    phase 2 small molecule active

    1 trial

  22. CYSTAGON 50 mg hard capsules

    The George Institute

    Pulmonary Tuberculosis

    phase 2 small molecule active

    1 trial

  23. Calquence 100 mg film-coated tablets, Calquence 100 mg hard capsules

    Lacuna Pharma Pty Ltd

    Waldenström Macroglobulinemia

    phase 2 small molecule active

    1 trial

  24. Calquence 100 mg film-coated tablets, Calquence 100 mg hard capsules

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory marginal zone lymphoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources